Peanut Allergy - Pipeline Review, H1 2015

05:01 EDT 8 Jun 2015 | BioPortfolio Reports

Recently added to the BioPortfolio report store, Peanut Allergy - Pipeline Review, H1 2015 is a new report from Global Markets Direct published on 2015-04-28. This 57-page report is available in PDF from $2000.

Peanut Allergy - Pipeline Review, H1 2015


Global Markets Direct’s, ‘Peanut Allergy - Pipeline Review, H1 2015’, provides an overview of the Peanut Allergy’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Peanut Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peanut Allergy and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


- The report provides a snapshot of the global therapeutic landscape of Peanut Allergy
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Peanut Allergy and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Peanut Allergy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Peanut Allergy pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of…

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Peanut Allergy Overview 7
Therapeutics Development 8
Pipeline Products for Peanut Allergy - Overview 8
Pipeline Products for Peanut Allergy - Comparative Analysis 9
Peanut Allergy - Therapeutics under Development by Companies 10
Peanut Allergy - Therapeutics under Investigation by Universities/Institutes 11
Peanut Allergy - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Peanut Allergy - Products under Development by Companies 14
Peanut Allergy - Products under Investigation by Universities/Institutes 15
Peanut Allergy - Companies Involved in Therapeutics Development 16
BioTech Tools s.a. 16
DBV Technologies S.A. 17
HAL Allergy BV 18
Immunomic Therapeutics, Inc. 19
Peanut Allergy - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 26
Allergen for Peanut Allergy - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Allergen for Peanut Allergy - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Allergen for Peanut Allergy - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
ARA-LAMP-Vax - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
DBV-712 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
DN-1017 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
PER-1080 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
pnut-ASIT - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Recombinant Protein for Peanut Allergy - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Recombinant Vector Vaccine for Peanut Allergy - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
VTC-064 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Peanut Allergy - Recent Pipeline Updates 39
Peanut Allergy - Dormant Projects 44
Peanut Allergy - Discontinued Products 45
Peanut Allergy - Product Development Milestones 46
Featured News & Press Releases 46
Apr 09, 2015: DBV Technologies Receives FDA Breakthrough Therapy Designation for Viaskin Peanut for the Treatment of Peanut Allergy in Children 46
Mar 25, 2015: Immunomic Therapeutics Receives Positive Feedback From FDA Following Pre-IND Discussions for Its Proprietary Peanut Allergy Vaccine 46
Feb 24, 2015: Viaskin Data Presented at AAAAI Meeting Show Safety and…

For more information open Peanut Allergy - Pipeline Review, H1 2015.


Original Article: Peanut Allergy - Pipeline Review, H1 2015


More From BioPortfolio on "Peanut Allergy - Pipeline Review, H1 2015"

Quick Search


Relevant Topics

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

The term allergy is used to describe a response, within the body, to a substance, which is not necessarily harmful in itself, but results in an immune response and a reaction that causes symptoms and disease in a predisposed person, which in turn can cau...

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...